^
Association details:
| Biomarker: | CFB overexpression |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
Published date:
07/14/2015
Excerpt:
...the efficacy of sunitinib, a multikinase VEGF inhibitor, in patients with relapsed/refractory GE/oesophageal cancer...Progression-free survival at 24 weeks was 8% (n=2 patients; confidence interval (CI): 95% 1.4-22.5%), and the duration of best response for the patients was 23 and 72 weeks...Overall response rate is 13%. Median PFS is 7 weeks (95% CI: 5.6-11.4 weeks) and the median overall survival is 17 weeks (95% CI: 8.9-25.3 weeks)....patients with clinical benefit from sunitinib had higher tumour CFB expression...
DOI:
10.1038/bjc.2015.197
Trial ID:
